APOE and Alzheimer disease: The goal of this study was to evaluate the activity of longer-term candesartan cilexetil treatment at modulating behavior and other markers of AD-relevant pathology in mice that express human APOE4. To address this goal, female (6–10-month treatment duration) and male (8–12-month treatment duration) E4FAD− and E4FAD+ mice were treated with either vehicle (0 mg/kg/day), 1 mg/kg/day candesartan cilexetil, or 10 mg/kg/day candesartan cilexetil in hydrogel.